Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | HTR1A | P08908 | 8/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641037 | 0.84 | AURKA (0.44) | DRD2DRD3HTR2ASLC6A4HTR1A | |
| SCHEMBL2641164 | 0.84 | HRH3 (0.36) | — | |
| SCHEMBL2641201 | 0.83 | AURKA (0.42) | — | |
| SCHEMBL5239845 | 0.82 | HTR3E (0.43) | DRD2DRD3HTR1AKDM4E | |
| SCHEMBL2641109 | 0.82 | HTR2C (0.39) | HTR2A | |
| Hydrochloric Acid SCHEMBL2641413 | 0.82 | HTR3E (0.43) | DRD2DRD3HTR1AKDM4E | |
| SCHEMBL2641292 | 0.79 | HTR2C (0.41) | DRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL5240101 | 0.79 | KDM4E (0.35) | DRD2HTR2ASLC6A4HTR1AKDM4E | |
| SCHEMBL2641252 | 0.79 | HTR2C (0.37) | HTR2A | |
| SCHEMBL2639270 | 0.78 | HTR2C (0.39) | DRD2HTR2ASLC6A4HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4831966-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | claimed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | claimed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | claimed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | claimed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | claimed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | DRD2 48/4885DRD3 95/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.